SynthesisBMC cancer2019

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials.

Martin Connock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.